Tag archive for ‘Adolor Corporation’
Cubist Makes Attractive Bid for Adolor
Investment View of the Proposed Acquisition Cubist announced today that it had signed a definitive agreement to acquire Adolor. Adolor has been one of my four recommendations. My price target was $4.50 in 2013 based on sales and earnings of Entereg alone and before taking into account the potential for ADL5945. Please refer to […]
Cubist Makes Attractive Takeover Bid for Adolor (ADLR, $1.91)
Investment View of the Proposed Acquisition Cubist announced today that it had signed a definitive agreement to acquire Adolor. Adolor has been one of my four recommendations. My price target was $4.50 in 2013 based on sales and earnings of Entereg alone and before taking into account the potential for ADL5945. This acquisition gives current […]
Check with Adolor Management on Entereg Marketing Transition and Progress of Partnering Discussions on ADL 5945 (ADLR, $2.05)
Investment Thesis I upgraded Adolor to a BUY after the company announced that it had reacquired all rights to Entereg from Glaxo. I did this even though binary phase II data on ADL 5945, their new drug for opioid induced constipation, was due at any time. I felt that the stock was attractive on the […]
Phase II Data for ADL 5945 in Opiod Induced Constipation is Excellent (ADLR, $2.23)
On a first quick review of the data from the phase II trial of ADL 5945 in chronic non-cancer pain patients with opioid-induced constipation, it looks like the efficacy and safety profile are excellent. The drug should enter a phase III trial and Adolor should be able to find a partner to fund much of […]
Prospects for Entereg May Justify $4.50 Price Target for 2013 (ADLR, $2.20)
Overview I recommended the purchase of Adolor in a report issued on June 19. This followed my initiation report of February 18. The catalyst for my upgrade was the announcement that Adolor was successful in regaining all rights to Entereg from GlaxoSmithKline (GSK) on favorable terms. The two companies had been co-marketing the drug and […]
Upgrading to Buy Based On Regaining Glaxo’s Rights in Entereg (ADLR, $1.65)
Investment Thesis Adolor has gained back Glaxo’s rights to Entereg (alvimopan) in a transaction that I regard as a highly positive, company changing event. Entereg has the critical sales mass to enable Adolor to be a self-sufficient, cash flow positive company. I believe that the Entereg sales run rate entering 2012 could be on the […]
Analysis of Adolor’s 1Q, 2011 and A Look Forward (ADLR, $1.39)
Entereg Results in the Quarter Were Excellent Entereg achieved sales of $7.5 million which was an increase of 41% from 1Q, 2010 and a slight sequential increase from the $7.3 million of 4Q, 2010. The company reported that the Entereg business is now operating at an annual run rate of $30 million, a level at […]
Initial Report on Adolor (ADLR, $1.38)
Adolor as a Stock While I am currently neutral on Adolor, it is a stock that I am watching closely. To become more positive, I need to gain more confidence that their lead drug Entereg, which has had a slower than expected sales ramp up since its introduction in 3Q, 2008 can grow from a […]